SCHEMBL21669232

SCHEMBL21669232

CCOC(O)C(NC(=O)OC(C)(C)C)c1ccc(OC(=O)CCS(=O)(=O)O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
KMT2A Q03164 3/20 0.35
GAA P10253 3/20 0.34
HPGD P15428 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
HIF1A Q16665 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GLA P06280 1/20 0.34
ABCB1 P08183 3/20 0.34
HTT P42858 4/20 0.34
LMNA P02545 3/20 0.34
HSD17B10 Q99714 3/20 0.34
TP53 P04637 2/20 0.34
XBP1 P17861 2/20 0.34
MAPK1 P28482 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
JAK2 O60674 1/20 0.34
S1PR4 O95977 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21669239 0.90 PPARG (0.38) PPARGPPARAKMT2AGAAHPGD
SCHEMBL24282880 0.90 ALDH1A1 (0.37) PPARGPPARAKMT2AGAAHPGD
SCHEMBL21669352 0.86 KMT2A (0.41) KMT2AGAAALDH1A1MAPTHIF1A
SCHEMBL21669247 0.84 PPARG (0.46) PPARGPPARAHPGDALDH1A1MAPT
SCHEMBL21669233 0.83 CA1 (0.43) KMT2ALMNATP53MMP13ELANE
SCHEMBL21669296 0.81 KMT2A (0.38) KMT2AALDH1A1MAPTHIF1AHTT
SCHEMBL24282828 0.81 ALDH1A1 (0.36) PPARGPPARAKMT2AGAAHPGD
SCHEMBL24282724 0.78 MAPT (0.38) PPARGPPARAKMT2AGAAHPGD
SCHEMBL24283195 0.78 ALDH1A1 (0.38) PPARGPPARAKMT2AGAAHPGD
SCHEMBL21669317 0.77 KMT2A (0.41) KMT2AALDH1A1MAPTHIF1AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3829568-B1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON INC (US) 2023-09-06 EP disclosed
US-20220087967-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON, INC. 2022-03-24 US disclosed
WO-2020028348-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS ALZHEON, INC. (US) 2020-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220087967-A1 SULFOPROPANOIC ACID DERIVATIVES FOR TREATING NEURODEGENERATIVE DISORDERS PSEN1, APP, PSEN2 PPARG 571/4885PPARA 226/4885KMT2A 3892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.